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Abstract
Objective:  To  evaluate  neopterin  plasma  concentrations  in  patients  with  active  juvenile  idio-
pathic arthritis  (JIA)  and  correlate  them  with  disease  activity.
Methods:  Sixty  patients  diagnosed  as  active  JIA,  as  well  as  another  60  apparently  healthy
age- and  gender-matched  children  as  controls,  were  recruited  from  the  Pediatrics  Allergy
and Immunology  Clinic,  Ain  Shams  University.  Disease  activity  was  assessed  by  the  Juvenile
Arthritis Disease  Activity  Score  27  (JADAS-27).  Laboratory  investigations  were  performed  for  all
patients,  including  determination  of  hemoglobin  concentration  (Hgb),  erythrocyte  sedimenta-
tion rate  (ESR),  and  C-reactive  protein.  Serum  concentrations  of  tumor  necrosis  factor-alpha
(TNF-), interleukin-6  (IL-6),  monocyte  chemoattractant  protein-1  (MCP-1),  and  neopterin  were
measured.
Results: Signiﬁcant  differences  were  found  between  JIA  patients  and  controls  with  regard  to
the mean  levels  of  Hgb,  ESR,  TNF-,  IL-6,  and  MCP-1  (p  <  0.05).  A  statistically  signiﬁcant  higher
mean level  serum  neopterin  concentration  (p  <  0.05)  was  found  in  JIA  patients  (20.43  ±  8.73
nmol/L) than  in  controls  (6.88  ±  2.87  nmol/L)  (p  <  0.05).  Positive  signiﬁcant  correlations  were
detected  between  serum  neopterin  and  ESR,  TNF-,  IL-6,  MCP-1,  and  JADAS-27  (p  <  0.05).  No
correlation was  found  between  serum  neopterin  and  CRP  (p  >  0.05).  Multiple  linear  regres-
sion analysis  showed  that  JADAS-  27  and  ESR  were  the  main  variables  associated  with  serum
neopterin  in  JIA  patients  (p  <  0.05).
Conclusion:  The  elevation  of  plasma  neopterin  concentrations  in  early  JIA  patients  may  indicate
stimulation  of  immune  response.  Serum  neopterin  can  be  used  as  a  sensitive  marker  for  assaying
background  inﬂammation  and  disease  activity  score  in  JIA  patients.
© 2015  Sociedade  Brasileira  de  Pediatria.  Published  by  Elsevier  Editora  Ltda.  All  rights  reserved.
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Associac¸ão  de  neopterina  como  marcador  de  ativac¸ão do  sistema  imunológico  e
atividade  da  artrite  reumatoide  juvenil
Resumo
Objetivo:  avaliar  as  concentrac¸ões  plasmáticas  de  neopterina  em  pacientes  com  artrite
idiopática  juvenil  (AIJ)  ativa  e  correlacioná-las  com  a  atividade  da  doenc¸a.
Métodos:  Sessenta  pacientes  diagnosticados  com  AIJ  ativa,  bem  como  outras  60  crianc¸as
aparentemente  saudáveis  com  a  mesma  idade  e  sexo  no  grupo  de  controle,  foram  recrutados
da clínica  de  Alergia  e  Imunologia  Infantil  da  Universidade  Ain  Shams.  A  atividade  da  doenc¸a  foi
avaliada  pelo  Escore  de  Atividade  da  Doenc¸a  da  Artrite  Juvenil  em  27  Articulac¸ões  (JADAS-27).
Foram realizadas  investigac¸ões  laboratoriais  em  todos  os  pacientes,  incluindo  a  determinac¸ão
da concentrac¸ão  de  hemoglobinas,  a  taxa  de  sedimentac¸ão  de  eritrócitos  e  a  proteína  C-reativa.
Foram mensuradas  as  concentrac¸ões  séricas  do  fator  de  necrose  tumoral  alfa,  interleucina-6  e
proteína quimiotática  de  monócitos-1  e  neopterina.
Resultados:  Foi  encontrada  uma  diferenc¸a  signiﬁcativa  entre  os  pacientes  com  AIJ  e  os  con-
troles quanto  às  médias  de  Hb,  TSE,  FNT-,  IL-6  e  MCP-1  (p  <  0,05).  Foi  encontrado  um  nível
estatística  e  signiﬁcativamente  maior  de  concentrac¸ão  média  de  neopterina  sérica  (p  <  0,05)
em pacientes  com  AIJ  (valor  médio  de  20,43  ±  8,73  nmol/L)  que  em  controles  (valor  médio
de 6,88  ±  2,87  nmol/L)  (p  <  0,05).  Foram  detectadas  correlac¸ões  positivas  signiﬁcativas  entre  a
neopterina sérica  e  a  TSE,  FNT-,  IL-6,  MCP-1  e  JADAS-27  (p  <  0,05).  Não  foi  encontrada  nen-
huma correlac¸ão  entre  a  neopterina  sérica  e  a  PCR  (p  >  0,05).  A  análise  de  regressão  linear
múltipla mostrou  que  o  JADAS-27  e  a  TSE  foram  as  principais  variáveis  associadas  à  neopterina
sérica em  pacientes  com  AIJ  (p  <  0,05).
Conclusão:  A  elevac¸ão  das  concentrac¸ões  plasmáticas  de  neopterina  em  pacientes  com  AIJ
precoce pode  indicar  um  estímulo  de  resposta  imune.  A  neopterina  sérica  pode  ser  usada  como
um indicador  sensível  para  analisar  o  histórico  de  inﬂamac¸ões  e  o  escore  de  atividade  da  doenc¸a
em pacientes  com  AIJ.
© 2015  Sociedade  Brasileira  de  Pediatria.  Publicado  por  Elsevier  Editora  Ltda.  Todos  os  direitos
reservados.
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controls  (Group  2).  Patients  were  recruited  from  the  Pedi-Introduction
Juvenile  idiopathic  arthritis  (JIA)  is  generally  considered  a
clinical  syndrome  involving  several  disease  subsets,  with
a  number  of  inﬂammatory  ﬂows,  leading  to  an  eventual
common  pathway  in  which  persistent  synovial  inﬂammation
and  associated  damage  to  articular  cartilage  and  underly-
ing  bone  are  present.1 One  main  inﬂammatory  process  in
the  pathophysiology  of  the  JIA  consists  of  overproduction
of  tumor  necrosis  factor  that  leads  to  overproduction  of
many  cytokines  such  as  interleukin-6,  which  causes  per-
sistent  inﬂammation  and  joint  destruction.2--4 The  disease
arises  in  a  genetically  susceptible  individual  due  to  envi-
ronmental  factors.5 Moreover,  it  has  been  proposed  that  an
antigen-driven  autoimmune  process  mediates  the  inﬂamma-
tory  pathology  in  some  cases  of  arthritis  (e.g.,  oligoarthritis,
polyarthritis).  In  contrast,  there  are  no  signs  of  lymphocyte-
mediated,  antigen-speciﬁc  immune  responses  in  individuals
with  systemic  onset  disease.  Recent  investigations  in  the
pathophysiology  of  systemic  onset  disease  have  indicated
that  this  disorder  is  due  to  an  uncontrolled  activation  of
the  innate  immune  system.6 Regardless  of  the  differences
in  the  underlying  pathogenesis  of  the  various  types  of  JIA,
pro-inﬂammatory  cytokines  are  consistently  overproduced
and  are  related  to  the  clinical  manifestations  in  all  types  of
JIA.7
a
W
eThe  International  League  of  Associations  for  Rheuma-
ology  (ILAR)  classiﬁcation  system  divides  JIA  into  seven
linical  subgroups.8 The  few  population  based  estimates
vailable  indicate  that  the  prevalence  of  JIA  is  approxi-
ately  one  to  two  per  1,000  children,  and  the  incidence
s  11  to  14  new  cases  per  100,000  children.9
Neopterin,  a  pyrazino-pyrimidine  compound,  is  syn-
hesized  by  monocytes  and  macrophages  in  response  to
nterferon- (IFN-) produced  by  activated  T-cells.  It  is  a
arker  of  cellular  immune  response,  and  levels  are  elevated
n  conditions  of  T-cell  or  macrophages  activation,  including
utoimmune  diseases  such  as  systemic  lupus  erythematosus
nd  rheumatoid  arthritis.10,11
The  current  study  was  undertaken  to  assess  the  associ-
tion  of  plasma  level  of  neopterin  with  inﬂammatory  and
isease  activity  in  JIA  patients.
ubjects and methods
he  present  study  included  60  patients  (30  males  and  30
emales)  diagnosed  as  active  JIA  (Group  1)  as  well  as  60
pparently  healthy  age-  and  gender-matched  children  astrics  Allergy  and  Immunology  Clinic,  Ain  Shams  University.
ritten  informed  consent  was  obtained  from  parents  after
xplanation  of  the  aim  of  the  study.  The  protocol  and  all
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Table  1  Demographic,  biochemical,  and  disease  characteristics  of  all  subjects.
JIA  Control  p
Mean ±  SD  Mean  ±  SD
Age  (years) 12.20  ±  2.80 12.84  ±  2.46 >  0.05
Sex (No.  M/F)  30/30  30/30
Hgb (g/dL)  9.24  ±  2.82  12.66  ±  3.66  <  0.001a
ESR  (mm/h)  50.64  ±  13.43  16.82  ±  4.35  <  0.001a
CRP  (mg/L)  10.42  ±  3.20
TNF- (pg/mL)  9.34  ±  1.44  2.4  ±  0.58  <  0.001a
IL-6  (pg/mL)  30.76  ±  8.28  5.26  ±  2.44  <  0.001
MCP-1 (pg/mL)  300.33  ±  78.25  100.56  ±  40.34  <  0.001a
Neopterin  (nmol/L) 20.43  ±  8.73 6.88  ±  2.87 <  0.001a
JADAS-27  40.34  ±  8.24
JIA, juvenile idiopathic arthritis; Hgb, hemoglobin concentration; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; TNF-
, tumor necrosis factor-alpha; IL-6, interleukin-6; MCP-1, monocyte chemoattractant protein-1; JADAS-27, Juvenile Arthritis Disease
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a p < 0.001 is highly signiﬁcant.
orresponding  documents  were  approved  by  Ethical  and
esearch  Committee  of  the  National  Research  Center.  Age
anged  from  5  to  15  years  with  a  mean  age  12.20  ±  2.8
ears.  Patients  were  eligible  if  they  met  the  Edmonton  Inter-
ational  League  of  Associations  for  Rheumatology  criteria
second  revision)  for  a  diagnosis  of  JIA.8 Disease  activ-
ty  was  measured  using  a  validated  score,  the  JADAS-27
Juvenile  Arthritis  Disease  Activity  Score-27).12 This  score
ncludes  four  measures:  physician  global  assessment  of  dis-
ase  activity  using  a  visual  analog  scale  (VAS),  parent  global
ssessment  of  child’s  well-being  determined  by  a  VAS,  count
f  joints  with  active  disease  (evaluating  27  joints),  and
rythrocyte  sedimentation  rate  (ESR).  ESR  is  normalized  to
 score  ranging  from  0  to  10,  by  the  formula  (ESR-20)/10.
ADAS-27  is  calculated  as  the  simple  linear  sum  of  the  scores
f  its  four  components,  which  yields  a  total  score  of  0-57,
ith  higher  scores  associated  with  worse  disease  activity.
hirty-eight  patients  (63.3%)  had  polyarticular  onset  JIA,  15
atients  (25%)  had  pauciarticular  onset,  and  seven  patients
11.7%)  had  systemic  onset.
All  patients  had  full  history  taken  and  were  subjected
o  clinical  examination.  Laboratory  investigations  were
erformed  for  all  patients,  including  determination  of
emoglobin  concentration  (Hgb  in  g/dL),  ESR  in  mm/h
y  Westergren  method,  and  C-reactive  protein  (CRP  in
g/L)  detection  by  the  latex  agglutination  slide  test.
erum  concentrations  of  tumor  necrosis  factor-alpha  (TNF-
),  interleukin-6  (IL-6),  and  monocyte  chemoattractant
rotein-1  (MCP-1)  were  measured  by  multiplex  enzyme-
inked  immunosorbent  assay  (ELISA)  (Millipore®,  Merck
gaA,  Darmstadt,  Germany).
ssay of serum neopterin (nmol/L)
erum  neopterin  levels  were  examined  using  an  ELISA  kit
Neopterin  ELISA,  IBL,  Hamburg,  Germany).  The  assay  is
ased  on  the  basic  principle  of  competition  between  a
eroxide-conjugated  and  non-conjugated  antigen  for  a  ﬁxed
umber  of  antibody  binding  sites.  The  peroxidase  conju-
ated,  antigen-antibody  complexes  bind  to  the  wells  of  the
icro  ﬁlter  strips,  which  are  coated  with  a  good  anti-rabbit
i
s
dntibody.  Unbounded  antigen  is  then  removed  by  washing.
fter  the  substrate  reaction,  the  optical  density  is  measured
t  450  nm.  A  standard  curve  is  plotted  and  neopterin  concen-
ration  in  the  sample  is  determined  by  interpolation  from
he  standard  curve.
tatistical analysis
tatistical  analysis  was  performed  using  Statistical  Package
or  Social  Sciences  (SPSS)  version  16  for  Windows  (SPSS
nc.,  Chicago,  IL,  USA).  Continuous  data  were  expressed  as
ean  ±  standard  deviation  and  were  compared  by  Student’s
-test.  Pearson’s  correlation  analysis  was  conducted  to  eval-
ate  the  association  between  continuous  exposure  and
ontinuous  covariates.  Multiple  linear  regression  analysis
as  performed  to  identify  the  inﬂuence  of  multiple  varia-
les  (age,  sex,  ESR,  CRP,  TNF-, IL-6,  MCP-1,  and  JADAS-27)
n  a  dependent  variable  (serum  neopterin).  p  <  0.05  was
onsidered  as  statistically  signiﬁcant.
esults
he  clinical  characteristics  of  patients  with  JIA  and  con-
rol  subjects  are  shown  in  Table  1.  No  signiﬁcant  difference
as  detected  between  patients  and  controls  as  regard  to
heir  mean  ages  (p  >  0.05).  However,  signiﬁcant  differences
ere  found  between  both  groups  with  regard  to  the  means
f  the  other  variables  (Hgb,  ESR,  TNF-, IL-6,  MCP-1,  and
eopterin;  p  < 0.05).
Demographic  and  biochemical  characteristic  were  com-
ared  between  males  and  females  in  the  patients  group  in
able  2.  Mean  JADAS-27  was  higher  in  females  than  in  males
nd  the  difference  was  signiﬁcant  (p  <  0.05),  while  no  sig-
iﬁcant  differences  were  detected  as  regard  to  the  other
ariables.The  correlations  between  serum  neopterin,  disease  activ-
ty,  and  inﬂammatory  mediators  in  patients  with  JIA  are
hown  in  Table  3.  Positive  signiﬁcant  correlations  were
etected  between  serum  neopterin  and  ESR,  TNF-, IL-6,
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Table  2  Demographic,  biochemical,  and  disease  characteristics  in  male  and  female  JIA  patients.
Males  Females  p
Mean±SD Mean±SD
Age  (years) 12.15  ±  3.25 11.96  ±  2.76 >  0.05
Hgb (g/dL)  9.54  ±  3.36  9.16  ±  2.49  >  0.05
ESR (mm/h)  48.54  ±  11.63  51.47  ±  10.33  >  0.05
CRP (mg/L)  9.72  ±  2.47  12.47  ±  3.43
TNF- (pg/mL)  8.24  ±  1.46  10.04  ±  1.37  >  0.05
IL-6 (pg/mL)  29.46  ±  6.46  31.46  ±  4.67  >  0.05
MCP-1 (pg/mL)  295.33  ±  78.25  304.74  ±  38.23  >  0.05
Neopterin (nmol/L)  19.84  ±  7.49  20.16  ±  2.42  >  0.05
JADAS-27 38.56  ±  8.46 49.38  ±  10.36 <  0.05a
JIA, juvenile idiopathic arthritis; Hgb, hemoglobin concentration; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; TNF-
, tumor necrosis factor-alpha; IL-6, interleukin-6; MCP-1, monocyte chemoattractant protein-1; JADAS-27, Juvenile Arthritis Disease
Activity Score-27.
a p < 0.05 is signiﬁcant.
Table  3  Correlations  between  neopterin,  inﬂammatory
markers,  and  disease  activity  in  JIA  patients.
Neopterin
r  p
ESR  0.36  <  0.001a
CRP  0.08  >  0.05
TNF- 0.46  <  0.001a
IL-6  0.24  <  0.05b
MCP-1  0.32  <  0.001a
JADAS-27  0.33  <  0.001a
JIA, juvenile idiopathic arthritis; ESR, erythrocyte sedimen-
tation rate; CRP, C-reactive protein; TNF-, tumor necrosis
factor-alpha; IL-6, interleukin-6; MCP-1, monocyte chemoat-
tractant protein-1; JADAS-27, Juvenile Arthritis Disease Activity
Score-27.
Table  4  Multiple  linear  regression  analysis  for  neopterin
and different  independent  variables.
Variables  Neopterin  (r2 =  0.458)
Standardized    coefﬁcient  t  p
Age  0.065  0.710  >  0.05
Sex -0.018  -0.203  >  0.05
ESR 0.517  4.934  <  0.001a
CRP  0.230  1.934  >  0.05
TNF- 0.164  1.842  >  0.05
IL-6 0.315  1.872  >  0.05
MCP-1 0.232  1.723  >  0.05
JADAS-27  0.534  4.862  <  0.001a
JIA, juvenile idiopathic arthritis; ESR, erythrocyte sedimen-
tation rate; CRP, C-reactive protein; TNF-, tumor necrosis
factor-alpha; IL-6, interleukin-6; MCP-1, monocyte chemoat-
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b p < 0.05 is signiﬁcant.
MCP-1,  and  JADAS-27  (p  <  0.05).  No  signiﬁcant  correlation
was  found  between  serum  neopterin  and  CRP  (p  >  0.05).
Multiple  linear  regression  analysis  for  the  association  of
the  different  variables  with  serum  neopterin  is  shown  in
Table  4.  After  adjustment  for  age,  sex,  and  inﬂammatory
markers,  JADAS-27  and  ESR  were  the  main  predictors  for  the
high  neopterin  levels  seen  in  patients  with  JIA  (p  <  0.05).  The
effects  of  TNF-  , IL-6,  and  MCP-1  were  attenuated  by  the
adjustment  of  all  the  variables.
Discussion
The  present  study  showed  a  high  level  of  serum  neopterin,
as  a  marker  of  macrophage  activation,  in  patients  with
JIA.  Neopterin  and  ESR  are  signiﬁcant  predictors  for  disease
activity  in  such  patients.Previous  studies  of  neopterin  in  rheumatoid  arthri-
tis  (RA)  have  been  performed  to  deﬁne  the  relationship
between  neopterin  and  disease  activity.  Generally,  they
found  that  neopterin  correlated  with  disease  activity  in  RA
e
t
p
ctractant protein-1; JADAS-27, Juvenile Arthritis Disease Activity
Score-27.
a p < 0.001 is highly signiﬁcant.
nd  decreased  with  treatment.11,13,14 In  contrast  to  the  cur-
ent  study,  a  previous  study  in  Japan  detected  signiﬁcantly
ncreased  neopterin  in  SLE  (Systemic  Lupus  Erythematosus)
atients  (p  <  0.001)  but  not  in  RA  patients.  However,  patients
ith  RA  had  a  greater  concentration  of  neopterin  in  synovial
uid.15
Regarding  recent  studies,  Rho  et  al.,  in  2011,16 showed
hat  neopterin  concentrations  were  signiﬁcantly  higher  in
atients  with  SLE  (median  8.0,  [6.5--9.8]  nmol/L)  and
A  (6.7,  [5.3--8.9]  nmol/L)  than  controls  (5.7,  [4.8--7.1]
mol/L),  and  were  higher  in  SLE  than  RA  (all  p  <  0.001).
n  SLE,  neopterin  was  signiﬁcantly  correlated  with  higher
SR  (p  =  0.001),  TNF- (p  <  0.001),  MCP-1  (p  =  0.005),  and
omocysteine  concentrations  (p  =  0.01),  but  in  RA  only  with
SR  (p  =  0.01).  The  results  of  this  study  were  in  agree-
ent  with  that  in  the  current  study.  In  2012,  Ozkan
t  al. evaluated  the  usefulness  of  tryptophan  degrada-
ion  and  neopterin  levels  in  active  rheumatoid  arthritis
atients  under  therapy.  They  found  that  neopterin  levels
orrelated  positively  with  kynurenine  (r  =  0.582,  p  <  0.02),
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156  
ynurenine/tryptophan  (r  =  0.486,  p  <  0.05),  erythrocyte
edimentation  rate  (r  =  0.472,  p  <  0.05),  and  RF  (r  =  0.478,
 <  0.05)  in  a  group  of  rheumatoid  arthritis  patients,  which
re  in  concordance  with  the  results  of  the  present  study.
owever,  contrary  to  the  present  results,  they  found  that
eopterin  and  TNF- levels  did  not  show  statistically  sig-
iﬁcant  differences  between  patient  and  control  groups.
he  difference  may  be  due  to  the  age  range  in  their  study,
s  it  was  adult  group.  In  2013,  D’agostino  et  al.18 evalu-
ted  neopterin  plasma  concentrations  in  patients  with  early
heumatoid  Arthritis  (RA)  and  correlated  them  with  dis-
ase  activity.  In  agreement  with  the  present  results,  they
etected  a  statistically  signiﬁcant  elevation  of  neopterin
ean  concentration  in  early  RA  patients:  mean  value  of
.92  ±  0.93  [3.94-28.3]  nmol/L  (p  <  0.001).  Pearson  prod-
ct  moment  correlation  suggested  a  correlation  between
eopterin  concentrations  and  DAS-28  (r  =  0.208,  p  =  0.065).
imilar  results  were  obtained  by  Arshadi  et  al.,19 who
etected  signiﬁcantly  higher  level  of  neopterin  in  RA
atients  compared  to  healthy  controls.  Moreover,  plasma
eopterin  level  was  increased  in  patients  with  active  disease
nd  also  was  correlated  with  disease  activity  parameters.
he  previous  results  are  in  concordance  with  the  present
tudy.  But  in  contrast  with  the  present  study,  they  found  a
igher  neopterin  level  in  male  RA  patients  versus  female
atients  and  a  signiﬁcant  correlation  of  plasma  level  of
eopterin  with  age  in  both  the  RA  and  control  group.  The
ifference  in  the  results  may  be  attributed  to  the  adult  age
roup  of  their  study  compared  to  the  young  age  group  in
he  present  study.  Also  Fagerer  et  al.,  in  2013,20 studied
he  involvement  of  speciﬁc  chemokines  in  the  inﬂammatory
rocess  of  patients  with  RA  and  cardiovascular  disease  with
ctivated  production  of  the  pteridine  neopterin.  In  agree-
ent  with  the  current  study,  they  found  high  neopterin
evels  in  RA  patients  and  signiﬁcantly  elevated  concentra-
ions  of  neopterin  in  patients  with  RA  plus  cardiovascular
isease  (CVD)  compared  to  RA  without  CVD  (p  <  0.03).
To  the  best  of  the  authors’  knowledge,  few  studies  have
ncluded  both  neopterin  as  a  pro-inﬂammatory  marker  and
IA.  Two  studies  found  high  serum  concentrations  of  IL-10,
L-18,  IL-6,  and  neopterin  in  patients  with  systemic  JIA  com-
licated  by  macrophage  activation  syndrome.  They  found
hat  IL-10  and  IL-18  remained  elevated  in  the  inactive  dis-
ase,  while  other  pro-inﬂammatory  cytokines  normalized  in
he  inactive  phase  of  the  disease.21,22 In  2014,  Brunner  et  al.
3 evaluated  tryptophan  as  biomarker  in  JIA  and  correlated
t  with  neopterin  in  serum  and  synovial  ﬂuid.  They  detected
hat  serum  tryptophan  showed  no  relevant  difference  in  JIA
atients  vs.  controls  in  contrast  to  neopterin,  which  was
igher  in  patients  than  controls.
The  present  study  has  several  limitations.  It  was  cross-
ectional  in  design,  and  therefore  causal  inferences  cannot
e  drawn.  Also,  the  effects  of  the  type  of  therapy  on
eopterin  levels  were  not  followed,  so  their  use  as  a  marker
or  therapy  efﬁcacy  cannot  be  evaluated.  The  relatively
mall  sample  size  could  be  responsible  for  inadequate  sta-
istical  power.  Larger  sample  sizes  would  have  increased
umbers  within  each  JIA  category,  allowing  for  greater  pre-
ision  in  assessing  the  pro-inﬂammatory  markers  between
ategories.
In  conclusion,  the  present  study  emphasized  that
acrophage  activation,  reﬂected  by  increased  serum
1Abu  Shady  MM  et  al.
eopterin,  is  a sensitive  marker  for  assaying  background
nﬂammation  and  disease  activity  score  in  JIA  patients.
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